Beta-lactamase inhibitors

Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145

Retrieved on: 
Wednesday, July 28, 2021
Health, Science, Pharmaceutical, Research, Clinical trials, Chemical compounds, Organic compounds, Heterocyclic compounds, Beta-lactamase, Antibiotic, Beta-lactamase inhibitors, β-Lactamase inhibitor, Pharmacokinetics, Cefepime, VNRX-7145, Venatorx Pharmaceuticals, Inc., VNRX-7145, VENATORX PHARMACEUTICALS, INC.

Venatorx Pharmaceuticals today announced positive top line results for its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial ( ClinicalTrials.gov NCT04243863 ) of VNRX-7145, a novel component of the investigational oral antibiotic combination product.

Key Points: 
  • Venatorx Pharmaceuticals today announced positive top line results for its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial ( ClinicalTrials.gov NCT04243863 ) of VNRX-7145, a novel component of the investigational oral antibiotic combination product.
  • The Phase 1 study was a 2-part, first-in-human dose-ranging study to evaluate the safety and pharmacokinetics (PK) of escalating oral doses of VNRX-7145.
  • Venatorxs two lead antibacterial clinical-stage programs are intravenous (cefepime-taniborbactam) and oral (ceftibuten/VNRX-7145) broad-spectrum beta-lactam/beta-lactamase inhibitor combinations that are in Phase 3 and Phase 1, respectively.
  • In addition, Venatorx is in Phase 1 with its first antiviral compound (VNRX-9945), a Hepatitis B virus inhibitor.

Qpex Biopharma Initiates Phase 1 Study of ORAvance™ for Oral Treatment of Drug-Resistant Gram-Negative Bacterial Infections

Retrieved on: 
Wednesday, May 12, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Beta-lactam antibiotics, β-lactam antibiotic, β-Lactamase inhibitor, Beta-lactamase, Biomedical Advanced Research and Development Authority, Beta-lactamase inhibitors, Antibiotics, Biocides, Drugs, Infectious diseases, Penicillins

The World Health Organization (WHO) has also prioritized development of new treatments for these pathogens.

Key Points: 
  • The World Health Organization (WHO) has also prioritized development of new treatments for these pathogens.
  • Two of the products use QPX7728, an ultra-broad-spectrum beta-lactamase inhibitor that restores the potency of beta-lactam antibiotics in vitro and in vivo.
  • Qpex\xe2\x80\x99s current collaboration with BARDA is focused on advancing a portfolio of novel antibiotics, including the QPX7728-based products OMNIvance and ORAvance.
  • For more information, please visit www.qpexbio.com and follow us on Twitter and LinkedIn .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005284/en/\n'

China Cefoperazone Sodium and Sulbactam Sodium Market Report 2021-2025: After the Implementation of the "4 + 7" Policy, Price May Decrease and Could Lead to Market Expansion

Retrieved on: 
Wednesday, April 21, 2021
Chemical compounds, Chemistry, Lactams, Organic compounds, Beta-lactamase inhibitors, Sulfones, Cefoperazone, Tetrazoles, Sulbactam, Sodium

b'DUBLIN, April 21, 2021 /PRNewswire/ -- The "Investigation Report on the Chinese Cefoperazone Sodium and Sulbactam Sodium Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nSales of the Cefoperazone Sodium and Sulbactam Sodium in China have an accelerated growth from 2017 to 2019.

Key Points: 
  • b'DUBLIN, April 21, 2021 /PRNewswire/ -- The "Investigation Report on the Chinese Cefoperazone Sodium and Sulbactam Sodium Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nSales of the Cefoperazone Sodium and Sulbactam Sodium in China have an accelerated growth from 2017 to 2019.
  • The revenue in 2019 is approximately CNY 1.57 billion in 2020, though it dropped about 13.69% compared to 2019.
  • In addition, after the implementation of the "4 + 7" policy (a plan for the centralized procurement), the price of Cefoperazone Sodium and Sulbactam Sodium may decrease, which could lead the market to expand in the future.\nCefoperazone Sodium and Sulbactam Sodium is an injectable antibiotic.
  • Therefore, the analyst predicts that in the next few years, the sales volume of Cefoperazone Sodium and Sulbactam Sodium will rise as the market expands.\n2 Sales of Cefoperazone Sodium and Sulbactam Sodium in China, 2016-2020\n2.3 Sales of Cefoperazone Sodium and Sulbactam Sodium by Dosage Form in China, 2016-2020\n3 Analysis of Major Cefoperazone Sodium and Sulbactam Sodium Manufacturers in China, 2016-2020\n3.3 Zhendong Health Industry Group Co. Ltd.\n3.5 Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd.\n3.6 Shenzhen Lijian Pharmaceutical Co., Ltd.\n4 Prices of Cefoperazone Sodium and Sulbactam Sodium for Different Manufacturers in China, 2020-2021\n4.2 Zhendong Health Industry Group Co. Ltd. (Musitan)\n4.4 Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (Xinkuaixin)\n4.5 Shenzhen Lijian Pharmaceutical Co., Ltd. (Lijianshu)\n5 Prospect of Chinese Cefoperazone Sodium and Sulbactam Sodium Drug Market, 2021-2025\n'

Investigation Report on the Chinese Cefoperazone Sodium and Sulbactam Sodium Markets, 2016-2020 & 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 15, 2021
Chemicals, Plastics, Manufacturing, Chemical compounds, Chemistry, Lactams, Organic compounds, Beta-lactamase inhibitors, Sulfones, Cefoperazone, Tetrazoles, Sulbactam, Sodium

b'The "Investigation Report on the Chinese Cefoperazone Sodium and Sulbactam Sodium Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nSales of the Cefoperazone Sodium and Sulbactam Sodium in China have an accelerated growth from 2017 to 2019.

Key Points: 
  • b'The "Investigation Report on the Chinese Cefoperazone Sodium and Sulbactam Sodium Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nSales of the Cefoperazone Sodium and Sulbactam Sodium in China have an accelerated growth from 2017 to 2019.
  • The revenue in 2019 is approximately CNY 1.57 billion in 2020, though it dropped about 13.69% compared to 2019.
  • In addition, after the implementation of the "4 + 7" policy (a plan for the centralized procurement), the price of Cefoperazone Sodium and Sulbactam Sodium may decrease, which could lead the market to expand in the future.\nCefoperazone Sodium and Sulbactam Sodium is an injectable antibiotic.
  • Therefore, the analyst predicts that in the next few years, the sales volume of Cefoperazone Sodium and Sulbactam Sodium will rise as the market expands.\n2 Sales of Cefoperazone Sodium and Sulbactam Sodium in China, 2016-2020\n2.3 Sales of Cefoperazone Sodium and Sulbactam Sodium by Dosage Form in China, 2016-2020\n3 Analysis of Major Cefoperazone Sodium and Sulbactam Sodium Manufacturers in China, 2016-2020\n3.3 Zhendong Health Industry Group Co. Ltd.\n3.5 Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd.\n3.6 Shenzhen Lijian Pharmaceutical Co., Ltd.\n4 Prices of Cefoperazone Sodium and Sulbactam Sodium for Different Manufacturers in China, 2020-2021\n4.2 Zhendong Health Industry Group Co. Ltd. (Musitan)\n4.4 Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (Xinkuaixin)\n4.5 Shenzhen Lijian Pharmaceutical Co., Ltd. (Lijianshu)\n5 Prospect of Chinese Cefoperazone Sodium and Sulbactam Sodium Drug Market, 2021-2025\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210415005555/en/\n'

Global Antibiotics Market (2020 to 2026) - by Action Mechanism, Drug Class and Region - ResearchAndMarkets.com

Retrieved on: 
Friday, March 26, 2021
Health, Pharmaceutical, Health sciences, Health, Articles, Beta-lactam antibiotics, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Beta-lactamase inhibitors, Antimicrobial resistance, β-Lactamase inhibitor, Antibiotic, Beta-lactamase

The "Global Antibiotics Market By Action Mechanism, By Drug Class, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Antibiotics Market By Action Mechanism, By Drug Class, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Global Antibiotics Market size is expected to reach $62.5 billion by 2026, rising at a market growth of 5.3% CAGR during the forecast period.
  • Presently, the demand for beta-lactam and beta-lactamase inhibitors class of antibiotics is more among healthcare providers.
  • Although, the development of antibiotic resistance and the rising cost of drug approval hinder the growth of the antibiotic market.

Qpex Biopharma Initiates Phase 1 Clinical Trial of QPX7728 for Drug-Resistant Bacterial Infections

Retrieved on: 
Thursday, December 3, 2020
Biotechnology, Pharmaceutical, General Health, Health, Infectious diseases, Hospitals, Clinical trials, Other Health, Chemical compounds, Organic compounds, β-Lactamase inhibitor, Chemistry, Beta-lactamase, Beta-lactamase inhibitors, Antibiotics, β-lactam antibiotic, Beta-lactam, Carboxylic acids, Drug resistance, Discovery and development of cephalosporins, QPX7728, Biomedical Advanced Research and Development Authority (BARDA) Partnership, Brii Biosciences Partnership, Antimicrobial Resistance (AMR), Qpex Biopharma

Today marks another important milestone for Qpex as we begin advancing three novel product candidates into clinical trials during the coming months, said Michael Dudley, Pharm.D., president and chief executive officer of Qpex Biopharma.

Key Points: 
  • Today marks another important milestone for Qpex as we begin advancing three novel product candidates into clinical trials during the coming months, said Michael Dudley, Pharm.D., president and chief executive officer of Qpex Biopharma.
  • We believe that QPX7728 has demonstrated a preclinical profile that exceeds that of recently marketed beta-lactamase inhibitors, as well as those in ongoing clinical trials.
  • Beta-lactamases are bacterial enzymes that destroy beta-lactam antibiotics and are the major mechanism of resistance to these drugs in gram-negative bacteria.
  • Qpex has a multi-product collaboration with Brii Biosciences for the development and commercialization of three of its products in greater China.

Collaborative Research by OpGen Group Company Ares Genetics and Johns Hopkins Researchers Demonstrates Potential of Next-Generation Sequencing for Investigation of Genetic Antimicrobial Resistance Mechanisms and Molecular Susceptibility Testing

Retrieved on: 
Wednesday, September 16, 2020
Articles, Branches of biology, Beta-lactam antibiotics, Drugs, Ceftolozane/tazobactam, Beta-lactamase inhibitors, Tazobactam, Beta-lactamase, Antimicrobial resistance, DNA sequencing, Pseudomonas aeruginosa, Karen Bush

To overcome antimicrobial resistance, ceftolozane-tazobactam has been introduced as a novel -lactam--lactamase inhibitor combination agent and received initial U.S. FDA approval in 2014.

Key Points: 
  • To overcome antimicrobial resistance, ceftolozane-tazobactam has been introduced as a novel -lactam--lactamase inhibitor combination agent and received initial U.S. FDA approval in 2014.
  • Findings demonstrate the potential of Next-Generation Sequencing (NGS) to investigate mechanisms of resistance by analyzing whole-genome sequencing data from P. aeruginosa isolates that developed resistance under treatment with ceftolozane-tazobactam.
  • The researchers propose extending ceftolozane-tazobactam infusions as a potential protective measure against acquired mutational resistance.
  • The present study is the result of an ongoing collaboration between Ares Genetics and the Johns Hopkins University School of Medicine, with the goal of investigating the diagnostic potential of NGS for antimicrobial susceptibility testing.

FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)

Retrieved on: 
Friday, June 5, 2020
Oncology, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Drugs, Enzymes, Carbapenem antibiotics, Organic compounds, Beta-lactam antibiotics, Beta-lactamase inhibitors, Thioethers, Relebactam, Enantiopure drugs, Carbapenem, Cilastatin, Imipenem, RECARBRIO (imipenem, cilastatin, and relebactam), Merck

RECARBRIO is contraindicated in patients with a history of known severe hypersensitivity to any component of RECARBRIO.

Key Points: 
  • RECARBRIO is contraindicated in patients with a history of known severe hypersensitivity to any component of RECARBRIO.
  • RECARBRIO is a combination of imipenem, a carbapenem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a beta-lactamase inhibitor.
  • RECARBRIO met the primary and key secondary endpoints, demonstrating non-inferiority to PIP/TAZ in 28-day all-cause mortality and clinical response at early follow-up, respectively.
  • Todays approval is further affirmation of Mercks steadfast commitment to meeting the needs of the health care community.

Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 ALLIUM Clinical Trial of EXBLIFEP® for Complicated Urinary Tract Infections

Retrieved on: 
Tuesday, February 25, 2020
Medical specialties, Medicine, Health, Infectious diseases, Penicillins, Beta-lactamase inhibitors, Diketopiperazines, Piperacillin, Wyeth, Tazobactam, Hospital-acquired infection, Urinary tract infection

Overall success was 79.1% for EXBLIFEP vs. 58.9% for piperacillin-tazobactam (adjusted stratified difference, 21.2% [95% stratified Newcombe CI, 14.3% to 27.9%]).

Key Points: 
  • Overall success was 79.1% for EXBLIFEP vs. 58.9% for piperacillin-tazobactam (adjusted stratified difference, 21.2% [95% stratified Newcombe CI, 14.3% to 27.9%]).
  • Treatment discontinuations were seen at comparable levels in 5.2% and 4.0% in EXBLIFEP and piperacillin-tazobactam respectively.
  • HAP is the second most common nosocomial infection (after urinary tract infections) and accounts for 1520% of the total.
  • Allecra is supported by Forbion, Andera Partners, Delos Capital, Xeraya Capital, EMBL Ventures, and BioMed Partners.

Global Antibiotics Market Analysis, Trends, and Forecasts, Report 2019-2025: Overview, Focus On Select Players, Trends & Drivers, Market Perspective

Retrieved on: 
Friday, October 25, 2019
Beta-lactam antibiotics, Chemical compounds, Organic compounds, β-Lactamase inhibitor, Beta-lactamase inhibitors, Beta-lactamase, Heterocyclic compounds, Penicillins, Beta-lactam

DUBLIN, Oct. 25, 2019 /PRNewswire/ -- The "Antibiotics - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 25, 2019 /PRNewswire/ -- The "Antibiotics - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market.
  • Poised to reach over US$20.5 Billion by the year 2025, Beta Lactam & Beta Lactamase Inhibitors will bring in healthy gains adding significant momentum to global growth.
  • In Japan, Beta Lactam & Beta Lactamase Inhibitors will reach a market size of US$1.2 Billion by the close of the analysis period.